Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
NCT05727904

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Led by Iovance Biotherapeutics, Inc. · Updated on 2026-04-03

670

Participants Needed

75

Research Sites

361 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.

CONDITIONS

Official Title

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or pathologically confirmed Stage IIIC, IIID, or IV unresectable or metastatic melanoma
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with life expectancy over 6 months
  • At least one resectable lesion (or combined lesions) available for lifileucel preparation
  • At least one measurable disease site as defined by RECIST 1.1 after tumor resection
  • Adequate organ function
  • Willingness to use highly effective birth control if of childbearing potential or having a partner of childbearing potential
  • Participants over 70 years may enroll after discussion with medical monitor
Not Eligible

You will not qualify if you...

  • Melanoma of uveal/ocular origin
  • Symptomatic untreated brain metastases
  • More than one prior line of therapy for metastatic disease
  • Prior therapy for metastatic disease
  • BRAF V600 mutation-positive tumors with prior adjuvant/neoadjuvant immune checkpoint inhibitor therapy only
  • Active major medical illnesses posing increased risk, such as systemic infections, seizure or coagulation disorders, or serious cardiovascular, respiratory, or immune conditions
  • Any primary or acquired immunodeficiency (e.g., SCID or AIDS)
  • Another primary malignancy within the past 3 years, except those not requiring treatment or curatively treated over 1 year ago with low recurrence risk
  • History of allogeneic cell or organ transplant
  • Other protocol-defined inclusion/exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 75 locations

1

University of Alabama at Birmingham: The Kirklin Clinic

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

City of Hope

Duarte, California, United States, 91010

Actively Recruiting

3

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States, 90007

Actively Recruiting

4

California Pacific Medical Center

San Francisco, California, United States, 94107

Actively Recruiting

5

University of Colorado Cancer Center

Aurora, Colorado, United States, 80045

Actively Recruiting

6

Orlando Health Cancer Institute

Orlando, Florida, United States, 32806

Actively Recruiting

7

University of Illinois Hospital & Health Sciences System

Chicago, Illinois, United States, 60612

Withdrawn

8

University of Kansas

Kansas City, Kansas, United States, 66205

Withdrawn

9

University of Louisville - James Graham Brown Cancer Center

Louisville, Kentucky, United States, 40202

Withdrawn

10

National Cancer Institute

Bethesda, Maryland, United States, 20814

Actively Recruiting

11

Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center

Detroit, Michigan, United States, 48201

Withdrawn

12

Henry Ford Health

Detroit, Michigan, United States, 48202

Actively Recruiting

13

Dartmouth-Hitchcock Medical Center (DHMC) - Norris Cotton Cancer Center

Lebanon, New Hampshire, United States, 03756

Actively Recruiting

14

MD Anderson Cancer Center at Cooper

Camden, New Jersey, United States, 08103

Actively Recruiting

15

Oncology Hematology Care

Cincinnati, Ohio, United States, 45226

Actively Recruiting

16

Ohio State University

Columbus, Ohio, United States, 43201

Actively Recruiting

17

St. Luke's Cancer Center - Anderson

Easton, Pennsylvania, United States, 18045

Withdrawn

18

Allegheny Health Network

Pittsburgh, Pennsylvania, United States, 15224

Actively Recruiting

19

Baptist Cancer Center

Bartlett, Tennessee, United States, 37920

Actively Recruiting

20

SCRI Oncology Partners

Nashville, Tennessee, United States, 37203

Actively Recruiting

21

Virginia Commonwealth University

Richmond, Virginia, United States, 23298

Withdrawn

22

Swedish Cancer Institute

Edmonds, Washington, United States, 98026

Actively Recruiting

23

Greenslopes Private Hospital

Greenslopes, Queensland, Australia, 4120

Actively Recruiting

24

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 3000

Actively Recruiting

25

Fiona Stanley Hospital

Murdoch, Western Australia, Australia, 6150

Actively Recruiting

26

Flinders Medical Centre

Bedford Park, Australia, 5042

Actively Recruiting

27

Westmead Hospital

Westmead, Australia, NSW 2145

Actively Recruiting

28

Universitair Ziekenhuis Brussel - Oncologisch Centrum

Jette, Belgium

Actively Recruiting

29

Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada, H2L 4M1

Actively Recruiting

30

Princess Margaret Cancer Centre

Toronto, Canada, M5G

Actively Recruiting

31

Institut Paoli Calmettes

Marseille, France, 13009

Actively Recruiting

32

Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu

Nantes, France, 44093

Actively Recruiting

33

Hopital Saint Louis

Paris, France, 75475

Actively Recruiting

34

Charité - Universitätsmedizin Berlin

Berlin, Germany, Germany, 13353

Actively Recruiting

35

Universitätsklinikum Carl Gustav Carus

Dresden, Germany, 1307

Actively Recruiting

36

Universitätsklinikum Hamburg-Eppendorf

Hamburg, Germany, 20251

Actively Recruiting

37

Universitätsklinikum Schleswig-Holstein - Campus Lübeck

Lübeck, Germany, 23562

Actively Recruiting

38

Klinikum Rechts der Isar der Technischen Universität München

Munich, Germany, 81675

Actively Recruiting

39

Hadassah Medical Center

Jerusalem, Israel

Actively Recruiting

40

Sheba Medical Center

Ramat Gan, Israel, 52621

Actively Recruiting

41

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel, 6423906

Actively Recruiting

42

Istituto Romagnolo per lo Studio dei Tumori

Meldola, Forlì-Cesena, Italy, 47014

Actively Recruiting

43

Centro di Riferimento Oncologico IRCCS

Aviano, Friuli Venezia Giulia, Italy, 33081

Actively Recruiting

44

Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale

Naples, Napoli, Italy, 80131

Actively Recruiting

45

Azienda Ospedaliero Universitaria Pisana

Pisa, Tuscany, Italy, 56100

Actively Recruiting

46

Istituto Europeo Di Oncologia

Milan, Italy, 20139

Withdrawn

47

Azienda Ospedaliera Universitaria Senese

Siena, Italy

Actively Recruiting

48

Nederlands Kanker Instituut

Amsterdam, Netherlands, 1066 CX

Actively Recruiting

49

Bundang Medical Center - CHA University

Seongnam-si, Gyeonggi-do, South Korea

Actively Recruiting

50

Samsung Medical Center

Seoul, South Korea, South Korea, 135-890

Actively Recruiting

51

Korea University Anam Hospital

Seoul, South Korea, 2841

Actively Recruiting

52

Seoul National University Hospital

Seoul, South Korea, 3080

Actively Recruiting

53

Severance Hospital, Yonsei University Health System

Seoul, South Korea, 3722

Actively Recruiting

54

Hospital Universitario Marques de Valdecilla

Santander, Cantabria, Spain, 39008

Actively Recruiting

55

Hospital Regional Universitario de Malaga - Hospital General

Málaga, Málaga, Spain, 29016

Actively Recruiting

56

Instituto Oncologico Rosell

Barcelona, Spain, 08028

Actively Recruiting

57

Hospital Universitari Vall dHebron

Barcelona, Spain, 08035

Withdrawn

58

Hospital Clinic de Barcelona

Barcelona, Spain, 8036

Actively Recruiting

59

ICO l'Hospitalet - Hospital Duran i Reynals

Barcelona, Spain, 8908

Actively Recruiting

60

Hospital General Universitario Gregorio Maranon

Madrid, Spain, 28007

Actively Recruiting

61

Hospital 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

62

Hospital Universitario Madrid Sanchinarro - CIOCC

Madrid, Spain, 28050

Actively Recruiting

63

Hospital Universitario Quirónsalud Madrid

Madrid, Spain, 28223

Actively Recruiting

64

Hospital Universitario Ramon y Cajal

Madrid, Spain

Actively Recruiting

65

Clínica Universitaria de Navarra

Pamplona, Spain, 31008

Actively Recruiting

66

Hospital Universitario Virgen Macarena

Seville, Spain, 41009

Actively Recruiting

67

Consorcio Hospital General Universitario de Valencia

Valencia, Spain, 46014

Actively Recruiting

68

Sahlgrenska Universitetssjukhuset

Gothenburg, Västra Götaland County, Sweden, SE-41346

Actively Recruiting

69

Centre Hospitalier Universitaire Vaudois Lausanne

Lausanne, Switzerland, 1011

Actively Recruiting

70

Queen Elizabeth Hospital Birmingham

Birmingham, England, United Kingdom, B15 2GW

Actively Recruiting

71

Freeman Hospital

Newcastle upon Tyne, England, United Kingdom, NE7 7DN

Actively Recruiting

72

Royal Marsden Hospital

Chelsea, London, United Kingdom, SW3 6JJ

Actively Recruiting

73

Beaston West of Scotland Canter Centre

Glasgow, United Kingdom, G120YN

Actively Recruiting

74

Guy's Hospital

London, United Kingdom, SE1 9RT

Actively Recruiting

75

Sarah Cannon Research Institute UK

London, United Kingdom, W1G 6AD

Actively Recruiting

Loading map...

Research Team

I

Iovance Biotherapeutics https://www.tilvance-301.com

CONTACT

I

Iovance Biotherapeutics Study Team

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | DecenTrialz